-
1
-
-
0014673226
-
Modification of parkinsonism: Chronic treatment with L-dopa
-
Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
-
(1969)
N Engl J Med
, vol.280
, pp. 337-345
-
-
Cotzias, G.C.1
Papavasiliou, P.S.2
Gellene, R.3
-
2
-
-
0023157703
-
Akathesia in idiopathic Parkinson's disease
-
Lang AE, Johnson K. Akathesia in idiopathic Parkinson's disease. Neurology 1987;37:477-481.
-
(1987)
Neurology
, vol.37
, pp. 477-481
-
-
Lang, A.E.1
Johnson, K.2
-
3
-
-
0017840794
-
Onset and end-of-dose levodopa-induced dyskinesias: Possible treatment by increasing the daily dose of levodopa
-
Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias: possible treatment by increasing the daily dose of levodopa. Arch Neurol 1978;35:261-263.
-
(1978)
Arch Neurol
, vol.35
, pp. 261-263
-
-
Lhermitte, F.1
Agid, Y.2
Signoret, J.L.3
-
4
-
-
0017468670
-
Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease
-
Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
-
(1977)
Mayo Clin Proc
, vol.52
, pp. 163-174
-
-
Muenter, M.D.1
Sharpless, N.S.2
Tyce, G.M.3
Darley, F.L.4
-
5
-
-
0025355032
-
Levodopa-induced dyskinesias: Review, observations, and speculations
-
Nutt JG. Levodopa-induced dyskinesias: review, observations, and speculations. Neurology 1990;40:340-345.
-
(1990)
Neurology
, vol.40
, pp. 340-345
-
-
Nutt, J.G.1
-
6
-
-
84984145377
-
Problems associated with long-term levodopa treatment of Parkinson's disease
-
Rinne UK. Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1983; 95(Suppl):19-26.
-
(1983)
Acta Neurol Scand
, vol.95
, Issue.SUPPL.
, pp. 19-26
-
-
Rinne, U.K.1
-
8
-
-
0013610466
-
The novel dopaminergic agent ropinirole selectively binds to cloned dopamine D3 receptors
-
Fears R, Bowen WP, Brown F, et al. The novel dopaminergic agent ropinirole selectively binds to cloned dopamine D3 receptors. Can J Neurol Sci 1993;20(Suppl 4):S68.
-
(1993)
Can J Neurol Sci
, vol.20
, Issue.4 SUPPL.
-
-
Fears, R.1
Bowen, W.P.2
Brown, F.3
-
9
-
-
0028971356
-
Ropinirole in the symptomatic treatment of Parkinson's disease
-
Brooks DJ, Torjansk N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm Suppl 1995;45:231-238.
-
(1995)
J Neural Transm Suppl
, vol.45
, pp. 231-238
-
-
Brooks, D.J.1
Torjansk, N.2
Burn, D.J.3
-
11
-
-
0027518471
-
Subtypes and localization of dopamine receptors in human brain
-
De Keyser J. Subtypes and localization of dopamine receptors in human brain. Neurochem Int 1993;22:83-93.
-
(1993)
Neurochem int
, vol.22
, pp. 83-93
-
-
De Keyser, J.1
-
12
-
-
0029895570
-
Comparative review of dopamine receptor agonists in Parkinson's disease
-
Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996;5:369-387.
-
(1996)
CNS Drugs
, vol.5
, pp. 369-387
-
-
Uitti, R.J.1
Ahlskog, J.E.2
-
13
-
-
0027500750
-
Treatment of Parkinson's disease
-
Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-1027.
-
(1993)
N Engl J Med
, vol.329
, pp. 1021-1027
-
-
Calne, D.B.1
-
14
-
-
0001904937
-
Drugs for Parkinson's disease, spasticity, and acute muscle spasms
-
Gilman AG, Rail TW, Nies AS, Taylor P, eds. New York: McGraw-Hill
-
Cedarbaum JM, Schleifer LS. Drugs for Parkinson's disease, spasticity, and acute muscle spasms. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: McGraw-Hill 1993;463-484.
-
(1993)
Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th Ed.
, pp. 463-484
-
-
Cedarbaum, J.M.1
Schleifer, L.S.2
-
15
-
-
0019307736
-
The role of D-1 and D-2 receptors
-
Schachter M, Bédard P, Debono AG, et al. The role of D-1 and D-2 receptors. Nature 1980;286:157-159.
-
(1980)
Nature
, vol.286
, pp. 157-159
-
-
Schachter, M.1
Bédard, P.2
Debono, A.G.3
-
17
-
-
0027160043
-
Glutamate-dopamine interactions in the basal ganglia: Relationship to Parkinson's disease
-
Greenamyre JT. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm Gen Sect 1993;91:255-269.
-
(1993)
J Neural Transm Gen Sect
, vol.91
, pp. 255-269
-
-
Greenamyre, J.T.1
-
18
-
-
0026607313
-
Levodopa-induced dyskinesia: Facts and fancy. What does the MPTP monkey model tell us?
-
Bédard PJ, Mancilla BG, Blanchette P, Gagnon C, Di Paolo T. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992;19:134-137.
-
(1992)
Can J Neurol Sci
, vol.19
, pp. 134-137
-
-
Bédard, P.J.1
Mancilla, B.G.2
Blanchette, P.3
Gagnon, C.4
Di Paolo, T.5
-
19
-
-
0029269229
-
The rationale for the use of dopamine agonists in Parkinson's disease
-
Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(Suppl 3):S6-S12.
-
(1995)
Neurology
, vol.45
, Issue.3 SUPPL.
-
-
Jenner, P.1
-
20
-
-
0028971703
-
Dopaminergic agonists in the treatment of Parkinson's disease: A review
-
Piccoli F, Riuggeri RM. Dopaminergic agonists in the treatment of Parkinson's disease: a review. J Neural Transm Suppl 1995;45:187-195.
-
(1995)
J Neural Transm Suppl
, vol.45
, pp. 187-195
-
-
Piccoli, F.1
Riuggeri, R.M.2
-
21
-
-
0026590683
-
Dopaminergic agonists in the treatment of Parkinson's disease
-
Goetz CG, Diederich NJ. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin 1992;10:527-540.
-
(1992)
Neurol Clin
, vol.10
, pp. 527-540
-
-
Goetz, C.G.1
Diederich, N.J.2
-
22
-
-
0002762924
-
Pharmacodynamics: Mechanisms of drug action and the relationship between drug concentration and effect
-
Gilman AG, Rail TW, Nies AS, Taylor P, eds. New York: McGraw-Hill
-
Ross EM. Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: McGraw-Hill, 1993:33-48.
-
(1993)
Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th Ed.
, pp. 33-48
-
-
Ross, E.M.1
-
23
-
-
0022658363
-
Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex
-
Beart PM, McDonald D, Cincotta M, de Vries DJ, Gundlach AL. Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex. Gen Pharmacol 1986;17:57-62.
-
(1986)
Gen Pharmacol
, vol.17
, pp. 57-62
-
-
Beart, P.M.1
McDonald, D.2
Cincotta, M.3
De Vries, D.J.4
Gundlach, A.L.5
-
24
-
-
84940137804
-
Differential binding of ergot compounds to human versus rat 5-HT2 cortical receptors
-
Hagen JD, Pierce PA, Peroutka SJ. Differential binding of ergot compounds to human versus rat 5-HT2 cortical receptors. Biol Signals 1994;3:223-229.
-
(1994)
Biol Signals
, vol.3
, pp. 223-229
-
-
Hagen, J.D.1
Pierce, P.A.2
Peroutka, S.J.3
-
25
-
-
0025317247
-
Pergolide: A review of its pharmacological potential in Parkinson's disease
-
Langtry HD, Clissold SP. Pergolide: a review of its pharmacological potential in Parkinson's disease. Drugs 1990;39:491-506.
-
(1990)
Drugs
, vol.39
, pp. 491-506
-
-
Langtry, H.D.1
Clissold, S.P.2
-
26
-
-
0021352630
-
In vitro selectivity of lisuride and other ergot derivatives for alpha 1- and alpha 2-adrenoceptors
-
McPherson GA. In vitro selectivity of lisuride and other ergot derivatives for alpha 1- and alpha 2-adrenoceptors. Eur J Pharmacol 1984;97:151-155.
-
(1984)
Eur J Pharmacol
, vol.97
, pp. 151-155
-
-
McPherson, G.A.1
-
27
-
-
0029025270
-
Dopamine agonists in the treatment of Parkinson's disease
-
Pahwa R, Koller WC. Dopamine agonists in the treatment of Parkinson's disease. Cleve Clin J Med 1995;62:212-217.
-
(1995)
Cleve Clin J Med
, vol.62
, pp. 212-217
-
-
Pahwa, R.1
Koller, W.C.2
-
29
-
-
0018380212
-
Effects of ergot drugs on serotonergic function: Behaviour and neurochemistry
-
Silberbergeld EK, Hruska RE. Effects of ergot drugs on serotonergic function: behaviour and neurochemistry. Eur J Pharmacol 1979;58:1-10.
-
(1979)
Eur J Pharmacol
, vol.58
, pp. 1-10
-
-
Silberbergeld, E.K.1
Hruska, R.E.2
-
33
-
-
0030741788
-
Attempts to obtain neuroprotection in Parkinson's disease
-
Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997;49(Suppl 1):S26-S33.
-
(1997)
Neurology
, vol.49
, Issue.1 SUPPL.
-
-
Olanow, C.W.1
-
34
-
-
0002852574
-
Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug naive MPTP-treated common marmosets
-
Pearce RKB, Banerji T, Jenner P, Marsden CD. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug naive MPTP-treated common marmosets [abstract]. Br J Pharmacol 1996;118:37P.
-
(1996)
Br J Pharmacol
, vol.118
-
-
Pearce, R.K.B.1
Banerji, T.2
Jenner, P.3
Marsden, C.D.4
-
35
-
-
0017690811
-
Investigations into the nature of the peri-oral movements induced by 2-(N,N-dipropyl) amino-5,6-dihydroxytetraline
-
Costall B, Naylor RJ, Owen RT. Investigations into the nature of the peri-oral movements induced by 2-(N,N-dipropyl) amino-5,6-dihydroxytetraline. Eur J Pharmacol 1977;45:357-367.
-
(1977)
Eur J Pharmacol
, vol.45
, pp. 357-367
-
-
Costall, B.1
Naylor, R.J.2
Owen, R.T.3
|